Review in Nephron, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00327860 (Chronic Kidney Disease in Children Prospective Cohort Study), which is not on this map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors at 5 institutions in 2 countries.
Ibrahim SandokjiDepartment of Pediatrics, Taibah University College of Medicine, Medina, Saudi Arabia, isandokji@gmail.com.
Yunwen XuDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Michelle DenburgDivision of Nephrology, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Susan FurthDivision of Nephrology, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Alison G AbrahamDepartment of Epidemiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Jason H GreenbergDepartment of Pediatrics, Section of Nephrology, Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA.
Children's Hospital of Philadelphia · USJohns Hopkins University · USTaibah University · SAUniversity of Colorado Anschutz Medical Campus · USYale University · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Chronic Kidney Disease in Children Study (C-Kid)U01DK066174 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SUSAN L. FURTH · 2003 to 2026
$25.1M
CKiD Cardiovascular Testing Travel SupplementU01DK066143 · NIDDK · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · PI Bradley Alan Warady · 2003 to 2026
$24.2M
The Kidney Disease in Children Data Management and Analysis Center (KIDMAC)U01DK066116 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI MUNOZ, ALVARO · 2003 to 2017
$17.9M
The Kidney Disease in Children Data Management and Analysis Center (KIDMAC)U24DK066116 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI Derek K Ng · 2018 to 2026
$12.6M
Central Biochemistry Laboratory of the CKiD ConsortiumU01DK082194 · NIDDK · UNIVERSITY OF ROCHESTER · PI SCHWARTZ, GEORGE J · 2008 to 2017
$3.5M
Patient Oriented Research in Pediatric Kidney DiseaseK24DK078737 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI FURTH, SUSAN L. · 2007 to 2016
$1.6M
Acute Kidney Injury in Children with Chronic Kidney DiseaseR01DK135650 · NIDDK · YALE UNIVERSITY · PI Jason Henry Greenberg · 2023 to 2026
$1.4M
Novel Biomarkers of Chronic Kidney Disease in ChildrenK08DK110536 · NIDDK · YALE UNIVERSITY · PI GREENBERG, JASON HENRY · 2016 to 2021
$882k
Chronic Kidney Disease Biomarkers Consortium (CKD BioCon) U01U01DK106982 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI DENBURG, MICHELLE, FURTH, SUSAN L. · 2015 to 2019
$817k
Metabolomic Profiling for Discovery of Biomarkers of Neurocognitive Impairment in Children with Chronic Kidney DiseaseR21AT009752 · NCCIH · CHILDREN'S HOSP OF PHILADELPHIA · PI DENBURG, MICHELLE · 2018 to 2019
backgroundDue to the complexity of chronic kidney disease (CKD) pathophysiology, biomarkers representing different mechanistic pathways have been targeted for the study and development of novel biomarkers. The discovery of clinically useful CKD biomarkers would allow for the identification of those children at the highest risk of kidney function decline for timely interventions and enrollment in clinical trials. SUMMARY: Glomerular filtration rate and proteinuria are traditional biomarkers to classify and prognosticate CKD progression in clinical practice but have several limitations. Over the recent decades, novel biomarkers have been identified from blood or urine with metabolomic screening studies, proteomic screening studies, and an improved knowledge of CKD pathophysiology. This review highlights promising biomarkers associated with the progression of CKD that could potentially serve as future prognostic markers in children with CKD. KEY MESSAGES: Further studies are needed in children with CKD to validate putative biomarkers, particularly candidate proteins and metabolites, for improving clinical management.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Current and Novel Biomarkers of Progression Risk in Children with Chronic Kidney Disease. · full record | Socratic